Watch PDSB. Know when insiders buy.
One email the day a filing lands. Free.
PDSB
PDS Biotechnology Corp
1.25
+0.28 +29.55%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
2
FLAG · shorts 2
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $69.7MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$33.7MNET DEBT $9.4M52W 0.20 – 1.60SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$6.5M | −$9.8M | — | -0.18 | −$2.8M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$6.5M | −$7.3M | — | -0.13 | −$4.4M | — | — | Aug 13 |
| Q4 2025 · Dec 31 | — | — | — | −$6.7M | −$7.6M | — | -0.14 | −$3.7M | $0 | −$3.7M | Mar 30 |
| Q3 2025 · Sep 30 | — | — | — | −$8.1M | −$9M | — | -0.19 | −$5.9M | $0 | −$5.9M | Mar 30 |
| Q2 2025 · Jun 30 | — | — | — | −$7.6M | −$9.4M | — | -0.21 | −$9.1M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$9.1M | −$8.5M | — | -0.21 | −$9M | — | — | Aug 13 |
| Q4 2024 · Dec 31 | — | — | — | −$7.4M | −$8M | — | -0.21 | −$8.2M | $0 | −$8.2M | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$10.2M | −$10.7M | — | -0.29 | −$8M | $1 | −$8M | Mar 30 |
| Q2 2024 · Jun 30 | — | — | — | −$8.7M | −$8.3M | — | -0.23 | −$8.9M | — | — | Mar 30 |
| Q1 2024 · Mar 31 | — | — | — | −$10.1M | −$10.6M | — | -0.30 | −$9.9M | — | — | Mar 30 |
| Q4 2023 · Dec 31 | — | — | — | −$10.4M | −$10.9M | — | -0.35 | −$8.5M | $0 | −$8.5M | Mar 27 |
| Q3 2023 · Sep 30 | — | — | — | −$10.5M | −$10.8M | — | -0.35 | −$7.2M | $0 | −$7.2M | Mar 27 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$31.5M | −$34.5M | — | -0.74 | −$27.8M | $0 | −$27.8M | — | — |
| FY2024 · to Dec 31 | — | — | −$36.3M | −$37.6M | — | -1.03 | −$35M | $29K | −$35.1M | — | — |
| FY2023 · to Dec 31 | — | — | −$43M | −$42.9M | — | -1.39 | −$33.6M | $0 | −$33.6M | — | — |
| FY2022 · to Dec 31 | — | — | −$41.7M | −$40.9M | — | -1.43 | −$25.7M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$21.4M | −$16.9M | — | -0.66 | −$12.5M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$14.9M | −$14.8M | — | -0.89 | −$13.1M | — | — | — | — |
Every number comes from PDS Biotechnology Corp's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.